Promethazine HCl Tablets Rx
Generic Name and Formulations:
Promethazine HCl 12.5mg+, 25mg+, 50mg; tabs; +scored.
Various generic manufacturers
Indications for Promethazine HCl Tablets:
Motion sickness. Perioperative nausea & vomiting.
Motion sickness: 25mg 30–60mins before travel; may repeat in 8–12hrs; maintenance 25mg twice daily. Perioperative nausea & vomiting: 25mg; may give additional doses of 12.5–25mg at 4–6hr intervals.
<2yrs: see Contraindications. Motion sickness: ≥2yrs: 12.5–25mg twice daily. Perioperative nausea & vomiting: 0.5mg/lb or 25mg; may give additional doses of 12.5–25mg or 0.5mg/lb at 4–6hr intervals.
Children <2yrs. Dehydrated or ill children (esp. Reye's syndrome). History of sleep apnea. Asthma and lower respiratory disorders. Uncomplicated nausea in children.
Glaucoma. GI or urinary obstruction. Cardiovascular or liver disease. Seizure disorders. Peptic ulcer. Bone marrow depression. Elderly. Children ≥2yrs. Pregnancy (Cat.C). Nursing mothers: not recommended.
Potentiates CNS depression with alcohol, other CNS depressants. Caution with MAOIs. May alter hCG pregnancy test results.
Drowsiness, lowered seizure threshold, cholestatic jaundice, anticholinergic and extrapyramidal effects, photosensitivity, hypo- or hypertension, rash, blood dyscrasias, nausea, neonatal platelet abnormalities; children: respiratory depression (may be fatal).
Formerly known under the brand names Phenergan (tabs, supps); Promethacon (supps).
Sign Up for Free e-newsletters
- Study Finds Association Between Folate Intake and Risk of Cutaneous Melanoma
- Melanoma Outcomes Improved With Nivolumab Alone or Plus Ipilimumab
- Oral Contraceptive Use May Not Be Associated With Increased Melanoma Risk
- The Caregivers' Cancer Journey
- Staff Education Leads to Increase in Oncology Rehabilitation Referrals
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
- Choice of Breast Reconstruction After Mastectomy Affects Satisfaction, Quality of Life
- Gender Bias in Medicine Has Far-Reaching Consequences
- Carfilzomib Benefits May Outweigh Cardiovascular Risk in Multiple Myeloma
- Patient Interest in Melanoma Genetic Risk Testing is Fairly High
- Genetic Link Between Depression and Breast Cancer Remains Unclear
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|